Most people diagnosed with breast cancer today live for many years with treatment, and the majority survive long term. The overall 5-year relative survival rate for female breast cancer is above 90%, meaning more than 9 in 10 women are alive five years after diagnosis. But that number varies enormously depending on how far the cancer has spread, what type it is, and your overall health going into treatment.
Survival Rates by Stage at Diagnosis
Stage at diagnosis is the single most powerful factor in determining how long you can expect to live with breast cancer. The National Cancer Institute’s SEER program tracks survival using three broad categories, based on data from 2016 to 2022:
- Localized (cancer confined to the breast): 100% 5-year relative survival
- Regional (spread to nearby lymph nodes): 87.5% 5-year relative survival
- Distant (metastasized to other organs): 33.8% 5-year relative survival
A “relative survival rate” compares breast cancer patients to people of the same age without cancer. A 100% rate for localized disease means those women are just as likely to be alive at five years as women who were never diagnosed. The majority of breast cancers, roughly two-thirds, are caught at this localized stage, which is why the overall survival picture is so favorable.
These are population averages, not individual predictions. Many women with regional disease live decades after treatment. And even with distant (stage IV) breast cancer, a third of women are alive at five years, a number that has been climbing as newer treatments reach patients.
How Breast Cancer Type Affects Survival
Not all breast cancers behave the same way. Tumors are classified by whether they have hormone receptors (HR) and a protein called HER2 on their surface, because these features determine which treatments will work. The 5-year relative survival rates by subtype tell a clear story:
- HR-positive/HER2-negative (the most common type): 95.8%
- HR-positive/HER2-positive: 92.2%
- HR-negative/HER2-positive: 87.0%
- Triple-negative (HR-negative/HER2-negative): 78.7%
Triple-negative breast cancer has the lowest survival rates because it lacks the receptors that hormone therapy and HER2-targeted drugs can latch onto, leaving fewer treatment options. Still, nearly 4 in 5 women with triple-negative breast cancer are alive at five years, and newer immunotherapy combinations have improved outcomes in recent years.
The gap between subtypes widens dramatically when cancer has spread. For distant (metastatic) disease, HR-positive/HER2-positive breast cancer has a 48.7% five-year survival rate, while distant triple-negative breast cancer drops to 14.9%. On the other hand, when any subtype is caught early, the differences nearly disappear: localized survival exceeds 92% regardless of subtype.
Living With Metastatic Breast Cancer
Stage IV breast cancer, where the disease has spread to bones, lungs, liver, or brain, is not typically curable. But “not curable” does not mean “not treatable.” Many women with metastatic breast cancer live for years, sometimes a decade or more, cycling through different treatment regimens as each one controls the disease for a period of time.
How long someone lives with metastatic breast cancer depends heavily on where it has spread and which subtype they have. Bone-only metastases tend to carry a better prognosis than spread to the liver or brain. HR-positive metastatic cancers often respond to a sequence of hormone-blocking therapies combined with newer targeted drugs, allowing women to maintain a reasonable quality of life for extended periods. HER2-positive metastatic disease, once considered especially aggressive, now has some of the best metastatic outcomes thanks to targeted antibody treatments developed over the past two decades.
The Risk of Late Recurrence
For women with hormone-receptor-positive breast cancer (the most common type), the timeline of risk extends well beyond the five-year mark that survival statistics typically measure. Analysis of long-term clinical trial data shows that the risk of recurrence runs about 1% per year on average for at least 20 years after the original diagnosis. That small yearly risk persists more or less indefinitely.
This is why many women with HR-positive breast cancer are recommended to take hormone-blocking medication for 5 to 10 years after initial treatment. It is also why ongoing monitoring matters. A woman who is cancer-free at year five still carries a meaningful cumulative risk over the following decade. At the same time, a 1% annual risk means 99% of women in any given year will not have a recurrence, so the odds remain strongly in your favor each year.
Triple-negative and HER2-positive breast cancers follow a different pattern. Recurrences tend to happen earlier, typically within the first three to five years. If you reach the five-year mark without recurrence for these subtypes, the risk drops substantially.
Other Health Conditions Matter More Than You Might Think
Survival statistics focus on cancer, but your overall health plays a large role in how long you live after a breast cancer diagnosis. Pre-existing conditions can significantly increase the risk of dying from any cause, sometimes rivaling the cancer itself as a threat.
Research published in the Journal of Clinical Oncology found that kidney disease and heart failure were the most significant comorbidities affecting overall mortality in breast cancer patients, each roughly doubling to tripling the risk of death compared to patients without those conditions. Diabetes increased mortality risk by about 60%, and cardiovascular disease and lung disease also had substantial effects. These impacts held regardless of race.
This means that for someone with early-stage breast cancer and a serious heart condition, managing the heart disease may be just as important for long-term survival as the cancer treatment itself. It also means that population survival statistics may overestimate or underestimate your personal outlook depending on your baseline health.
Breast Cancer Survival in Men
Men account for a small fraction of breast cancer diagnoses, and their outcomes are generally worse. A large study reported by the National Cancer Institute found that the 5-year overall survival rate was 77.6% for men compared to 86.4% for women. This gap is partly because men tend to be diagnosed at a later stage, often because neither they nor their doctors suspect breast cancer until it has progressed. Men also tend to be older at diagnosis and are less likely to receive guideline-recommended treatments.
What These Numbers Mean for You
Survival statistics describe what happened to large groups of people diagnosed in a specific time window. They cannot tell you exactly how long you will live. They also tend to lag behind current treatment options, since the women counted in today’s five-year data were diagnosed years ago, before some of the newest therapies were available.
Several factors tilt the odds in a meaningful way: being diagnosed early, having a hormone-receptor-positive subtype, being in good overall health, completing the recommended course of treatment, and staying on long-term preventive medications if prescribed. Women diagnosed with localized breast cancer today have an excellent chance of living a normal lifespan. Even those diagnosed with more advanced disease are living longer than at any previous point, as treatment options continue to expand.